Week of August 9th 2021 | Vol. 10, Issue 32
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
MAP International, a nonprofit health organization whose mission is to provide medicines and health supplies to those in need around the world so that they might experience life to the fullest, recently received a generous donation from Tanner Pharma Group.

The donation of over 18,000 units of pharmaceutical products and cash, valued at $250,000, will specifically benefit MAP International’s Bringing Children Health (BCH) program. The BCH program is a targeted initiative to increase global health equity for access to antibiotics for children in need, and the donation from Tanner Pharma Group included not only life-saving antibiotics, but also vital medicines like children’s fever reducer/pain reliever, and antifungal and anti-seizure medicines.

An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
2 transactions totaling $2,281 million
Supplies, Equipment & Services
4 transactions totaling $130 million
Healthcare IT & Managed Care
4 transactions
Healthcare Facilities & Distributors
2 transactions
Pharma & Biotech
8 transactions totaling $464 million
Supplies, Equipment & Services
16 transactions totaling $291 million
Healthcare IT & Managed Care
10 transactions totaling $228 million
Healthcare Facilities & Distributors
3 transactions totaling $18
Pharma & Biotech
10 transactions totaling $5,419 million
Supplies, Equipment & Services
1 transaction totaling $275 million
Healthcare IT & Managed Care
1 transactions totaling $1
Healthcare Facilities & Distributors
0 transactions
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
August 4, 2021 - Contact Pharma
Sanofi has entered into a definitive agreement to acquire Translate Bio, a clinical-stage mRNA therapeutics company, in a transaction valued at approximately $3.2 billion. Subject to customary closing conditions, the acquisition is expected to be completed in 3Q021. In June 2018, Sanofi and Translate Bio entered a collaboration and exclusive license agreement to develop mRNA vaccines which was further expanded in 2020 to address current and future infectious diseases.

August 5, 2021 - Contact Pharma
Amgen has unveiled plans to build a new $550 million biologics manufacturing facility in Holly Springs, NC, creating 355 jobs along the way. The new site in the Research Triangle area of North Carolina will bring a biologics drug substance manufacturing plant online to help the company continue to meet the production demands for its medicines.

August 6, 2021 - Fierce Healthcare
GoodRx struck a deal with medication data giant Surescripts to provide doctors and clinicians with more information about the cash price of drugs at the point of care. The partnership will significantly expand GoodRx's footprint as Surescripts has relationships with most electronic health record (EHR) vendors. The deal also expands the information healthcare providers have on cash pay drug pricing information. GoodRx, which went public last year and raised $1.1 billion in its IPO, built an online platform that offers coupons for discounts on prescription drugs.

August 6, 2021 - Contact Pharma
TriRx Pharmaceutical Services, an international contract development and manufacturing organization (CDMO), has finalized and closed on an agreement with Elanco Animal Health to acquire the ownership and operations of its manufacturing site in Shawnee, KS. Elanco is a global animal health company dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. The two companies also entered into a long-term supply agreement for this site.
Events Hosted or Attended by Bourne Partners

August 10-12, 2021 - Philadelphia, PA

October 20, 2021 - Charlotte, NC

November 9-11, 2021 - Milan, Italy

January 10-14, 2022 - San Francisco, CA
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.